PF-08634404 plus chemotherapy for extensive-stage small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial enrolls adults with newly diagnosed extensive-stage small cell lung cancer and gives PF-08634404 together with standard chemotherapy by IV. It has an initial safety/tolerability phase to determine how the medicine is handled with chemotherapy, followed by a randomized phase comparing PF-08634404 plus chemotherapy to the approved combination of atezolizumab plus chemotherapy. Participants must have measurable disease, good performance status (ECOG 0–1), and adequate organ function; treatments and follow-up visits occur at participating clinic sites. Outcomes include safety, tolerability, and comparative clinical outcomes such as tumor response and disease control.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
* Participants have not received systemic therapy (chemotherapy, radiotherapy, chemoradiation) for ES-SCLC.
* Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC
* Have at least one measurable lesion as the targeted lesion based on RECIST V1.1.
* Eastern Cooperative Oncology Group performance status of 0 or 1.
* Adequate organ function

Exclusion Criteria:

* known active CNS lesions, including brainstem, meningeal, or spinal cord metastases or compression
* Leptomeningeal disease
* Clinically significant risk of hemorrhage or fistula
* history of another malignancy within 3 years
* active autoimmune diseases requiring systemic treatment within the past 2 years

Where it's running

• Highlands Oncology Group
  Fayetteville, Arkansas, United States Recruiting
• Highlands Oncology Group
  Rogers, Arkansas, United States Recruiting
• Highlands Oncology Group
  Springdale, Arkansas, United States Recruiting
• BRCR Coral Springs
  Coral Springs, Florida, United States Recruiting
• Mid Florida Hematology and Oncology Center
  Orange City, Florida, United States Recruiting
• BRCR Global - Tamarac
  Tamarac, Florida, United States Recruiting

+32 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Multiomic analysis in relapsed small-cell lung cancer with DLL3 T cell engager

  This observational study tests how blood and tumor markers change over time in adults with relapsed small-cell lung cancer who are receiving a DLL3-targeted therapy, to see if those changes relate to clinical outcomes.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07795411

• 68Ga-YQ-CC05: a new probe for detecting tumors with CCK2R

  This study tests a radioactive probe called 68Ga-YQ-CC05 to see if it can safely help find tumors in adults with certain cancers using PET-CT imaging.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07914764

• Exploration of whole-brain radiotherapy with PD-1 inhibitors for brain injury in SCLC

  This study tests whether adding PD-1 inhibitors to chemotherapy and prophylactic brain irradiation helps some small cell lung cancer patients protect the brain.

  Recruiting Guizhou Medical University · Guiyang, Guizhou · NCT07905937

• Propranolol with Adebrelimab and Platinum Chemotherapy in Small Cell Lung Cancer

  This early-phase trial tests whether adding propranolol to adebrelimab plus platinum chemotherapy is safe and may help treat small cell lung cancer in adults.

  Recruiting Phase 1 Second Xiangya Hospital of Central South University · Changsha, Hunan and 3 other locations · NCT07886047

• IDP-121 plus chemotherapy in platinum-resistant small cell lung cancer

  This trial tests higher and higher doses of IDP-121 with chemotherapy to see if it is safe and workable for adults with advanced small cell lung cancer that progressed after first-line platinum therapy.

  Recruiting at 6 sites Phase 1/2 IDP Discovery Pharma S.L. · Barcelona and 9 other locations · NCT07864207

• Armored DLL3-SAVVYZ-IL18 CAR T cells for DLL3+ cancers

  Aims to see if DLL3-SAVVYZ-IL18 CAR T cells can be safely given to people with DLL3-positive cancers, including certain small cell lung cancers and other neuroendocrine tumors.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07783477

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.